Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- HLS.TO
- Price
- 4.31
- Stock movement up
- +0.28 (6.95%)
- Company name
- HLS Therapeutics Inc
- Exchange
- (TO ,
- Currency
- CAD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 137.03M
- Ent value
- 213.13M
- Price/Sales
- 2.33
- Price/Book
- 1.66
- Div yield
- 4.64%
- Div growth
- -
- Growth years
- -
- FCF payout
- 12.69%
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -1.08%
- 1 year return
- -16.63%
- 3 year return
- -34.01%
- 5 year return
- -24.22%
- 10 year return
- 6.72%
Last updated: 2025-04-15
DIVIDENDS
Dividend yield - 5y
Loading...
Dividend yield data
| Dividend per share | 0.20 |
| Dividend yield | 4.64% |
| Payout frequency | Quarterly |
| Maximum yield | 6.64% |
| Average yield | 2.81% |
| Minimum yield | 0.94% |
| Discount to avg yield | 39.47% |
| Upside potential | 65.22% |
| Yield as % of max yield | 69.84% |
Yield distribution (inverse percentile) - 5y
Loading...
Yield distribution data
| Dividend yield | 4.64% |
| Current yield distribution | 26.35% |
| Yield at 100% (Min) | 0.94% |
| Yield at 90% | 1.09% |
| Yield at 80% | 1.17% |
| Yield at 50% (Median) | 2.00% |
| Yield at 20% | 4.92% |
| Yield at 10% | 5.49% |
| Yield at 0% (Max) | 6.64% |
Dividend per share
Loading...
Dividend per share data
| Years of growth | - |
| CCC status | - |
| Dividend per share | 0.20 |
| Payout frequency | Quarterly |
| Ex-div date | 27 Apr 2023 |
| EPS (TTM) | -0.76 |
| EPS (1y forward) | -0.36 |
| EPS growth (5y) | -1.08% |
| EPS growth (5y forward) | - |
Dividend growth
Loading...
Please create a free account or log in to access this chart
Dividend growth data
| HLS.TO | S&P500 | |
| DGR MR | - | -13.74% |
| DGR TTM | - | 6.60% |
| DGR 3 years | - | 5.24% |
| DGR 5 years | - | 5.40% |
| DGR 10 years | - | 7.07% |
| DGR 15 years | - | 6.12% |
| Time since last change announced | 2435 days |
| EPS growth (5y) | -1.08% |
| EPS growth (5y forward) | - |
Payout ratio
Loading...
Please create a free account or log in to access this chart
Payout ratio data
| EPS coverage | FCF coverage | |
| TTM | -9.95% | 12.69% |
| Average | - | - |
| Forward | -55.56% | - |
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | 11.05 |
| Price to FCF | 7.25 |
| Price to EBITDA | 18.80 |
| EV to EBITDA | 29.24 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2.33 |
| Price to Book | 1.66 |
| EV to Sales | 3.62 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 31.79M |
| EPS (TTM) | -0.76 |
| FCF per share (TTM) | 0.60 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 58.89M |
| Gross profit (TTM) | 50.41M |
| Operating income (TTM) | -9.21M |
| Net income (TTM) | -24.09M |
| EPS (TTM) | -0.76 |
| EPS (1y forward) | -0.36 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 85.60% |
| Operating margin (TTM) | -15.64% |
| Profit margin (TTM) | -40.91% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 32.52M |
| Net receivables | 9.21M |
| Total current assets | 52.86M |
| Goodwill | 0.00 |
| Intangible assets | 136.39M |
| Property, plant and equipment | 0.00 |
| Total assets | 191.32M |
| Accounts payable | 12.32M |
| Short/Current long term debt | 83.07M |
| Total current liabilities | 26.12M |
| Total liabilities | 108.62M |
| Shareholder's equity | 82.71M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 12.40M |
| Capital expenditures (TTM) | 56.00K |
| Free cash flow (TTM) | 18.89M |
| Dividends paid (TTM) | 2.40M |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -29.13% |
| Return on Assets | -12.59% |
| Return on Invested Capital | -14.55% |
| Cash Return on Invested Capital | 11.41% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.07 |
| Daily high | 4.35 |
| Daily low | 4.00 |
| Daily Volume | 10K |
| All-time high | 25.50 |
| 1y analyst estimate | 6.03 |
| Beta | 1.07 |
| EPS (TTM) | -0.76 |
| Dividend per share | 0.20 |
| Ex-div date | 27 Apr 2023 |
| Next earnings date | 7 May 2025 |
Downside potential
Loading...
Downside potential data
| HLS.TO | S&P500 | |
| Current price drop from All-time high | -83.10% | -12.04% |
| Highest price drop | -98.67% | -56.47% |
| Date of highest drop | 2 Apr 2009 | 9 Mar 2009 |
| Avg drop from high | -62.80% | -11.07% |
| Avg time to new high | 178 days | 12 days |
| Max time to new high | 4480 days | 1805 days |
COMPANY DETAILS
Marketcap
137.03M
Marketcap category
Small-cap
Description
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
Employees
91
Investor relations
-
SEC filings
CEO
Country
Canada
City
Stock type
-
CCC status
-
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Key Insights Significant control over HLS Therapeutics by individual investors implies that the general public has more...
March 22, 2025
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces it...
March 13, 2025
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces th...
March 13, 2025
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q4 and fiscal 2024 financial results on Thursday, March 13, 2025. The Company will hold a conference call ...
February 27, 2025
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
February 21, 2025
Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we see...
January 11, 2025
HLS Therapeutics ( TSE:HLS ) Third Quarter 2024 Results Key Financial Results Revenue: US$14.1m (down 12% from 3Q...
November 8, 2024
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces it...
November 7, 2024
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 fiscal 2024 financial results on Thursday, November 7, 2024. The Company will hold a conference call th...
October 24, 2024
Key Insights Using the 2 Stage Free Cash Flow to Equity, HLS Therapeutics fair value estimate is CA$6.45 Current share...
October 16, 2024
Next page